When an FDA investigator pulls up an audit trail during an inspection, the question is not whether a company has a Part 11 policy. It is whether the systems running underneath that policy can actually prove what happened, who did it, and when. That gap between documented intent and operational reality is where most 483 observations originate, and it is narrower to close than most quality teams assume before they face it.
21 CFR Part 11, issued in 1997, answers a foundational question: can an electronic record carry the same legal weight as a paper one with a handwritten signature? The regulation says yes, under specific conditions. Those conditions cover validated systems, protected records with defined retention periods, access limited to authorized individuals, and secure computer-generated audit trails that cannot be altered or stripped without leaving a trace. The FDA’s 2018 guidance on scope and application reinforced a narrow interpretation: Part 11 does not create new documentation requirements on its own. It applies wherever a predicate rule, such as GMP or GCP, already demands a record that a company keeps electronically.
Electronic signature requirements add a second layer that catches organizations off guard more often than the records side does. Each signature must be unique to one person, permanently linked to its record, and carry a visible meaning: whether the signer approved, reviewed, or authored the document. A signature confirming only that “this action happened” fails the standard. Shared login credentials fail it immediately, because the agency requires that any signed action trace back to one verified individual. The most frequently cited violations in FDA Form 483 observations follow predictable patterns: disabled audit trails, shared accounts, systems placed into GMP use without documented validation, and password policies that were never enforced or updated after personnel changes.
An electronic quality management system built around Part 11 requirements handles most of this at the workflow level, enforcing correct signing sequences, generating time-stamped audit trails automatically, and flagging access anomalies rather than leaving those checks to periodic manual review. The practical difference is that compliance becomes a function of daily operation rather than a pre-inspection sprint. For organizations still relying on spreadsheets or loosely configured digital tools for GMP-required records, the validation documentation gap is likely the first place an investigator will look.
Source link: https://www.dotcompliance.com/blog/21-cfr-part-11/21-cfr-part-11-compliance-explained-and-how-eqms-helps/
Moe Alsumidaie is Chief Editor of The Clinical Trial Vanguard. Moe holds decades of experience in the clinical trials industry. Moe also serves as Head of Research at CliniBiz and Chief Data Scientist at Annex Clinical Corporation.
